Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cyteir Therapeutics's cash to debt ratio for the quarter that ended in Sep. 2023 was 8,077.63.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Cyteir Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.
The historical rank and industry rank for Cyteir Therapeutics's Cash-to-Debt or its related term are showing as below:
CYTT'
s Cash-to-Debt Range Over the Past 10 Years
Min: 165.49 Med: 8077.63 Max: No Debt
Current: 8077.63
During the past 4 years, Cyteir Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 165.49. And the median was 8077.63.
Cyteir Therapeutics Cash-to-Debt Historical Data
The historical data trend for Cyteir Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
|
Cyteir Therapeutics Annual Data
|
|
Trend |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
| Cash-to-Debt |
|
No Debt |
No Debt |
No Debt |
165.49 |
|
Cyteir Therapeutics Quarterly Data
|
|
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
| Cash-to-Debt |
|
|
|
|
|
|
|
|
|
|
|
170.99 |
165.49 |
1,400.04 |
2,344.47 |
8,077.63 |
Competitive Comparison
For the Biotechnology subindustry, Cyteir Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyteir Therapeutics Cash-to-Debt Distribution
For the Biotechnology industry and Healthcare sector, Cyteir Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Cyteir Therapeutics's Cash-to-Debt falls into.
Cyteir Therapeutics Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Cyteir Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:
Cyteir Therapeutics's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyteir Therapeutics (Cyteir Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
128 Spring Street, Building A, Suite 510, Lexington, MA, USA, 02421
Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor or MCT inhibitor, initially evaluated in a phase 1/2 study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard-of-care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy.
Executives
| Novo Holdings A/s |
10 percent owner |
TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
| Joseph S Zakrzewski |
director |
509 WATERVIEW PLACE, NEW HOPE PA 18938 |
| John F Thero |
director |
C/O AMARIN PHARMA, INC., 1430 ROUTE 6, BEDMINSTER NJ 07921 |
| Adam M Veness |
officer: General Counsel |
C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036 |
| Stephen H. Sands |
director |
128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421 |
| Jeffrey Humphrey |
director |
C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142 |
| Droia Invest Ii Scsp |
10 percent owner |
28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840 |
| Janwillem Naesens |
director |
128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421 |
| Sa Ihl |
10 percent owner |
28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840 |
| Karen Hong |
director |
69 PARKSIDE DRIVE, PRINCETON NJ 08540 |
| Bv Wepaven |
10 percent owner |
BRUSSELSESTEENWEG 11, MEISE C9 1860 |
| Luc Verelst |
10 percent owner |
28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840 |
| Df Ii Gp Sarl |
10 percent owner |
28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840 |
| Timothy Romberger |
director |
128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421 |
| Racquel Bracken |
director |
128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421 |
Cyteir Therapeutics (Cyteir Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CYTT has been successfully added to your